文献速递消化道肿瘤与早癌消化内镜

表观遗传预后检测对Barrett食管患者进行准确风险分层的验证

Validation of an Epigenetic Prognostic Assay to Accurately Risk-Stratify Patients With Barrett Esophagus.
PubMed 文献 · Am J Gastroenterol · 2024-08-14

该研究在6个中心240例Barrett食管患者的内镜活检组织中,用甲基化特异性生物标志物检测进行独立验证,按低危、低中危、高中危和高危四级分层。高危患者5年内进展为高级别上皮内瘤变或食管腺癌的风险是低危患者的15.2倍,高危组5年平均进展风险为21.5%,低危组仅为1.85%。

要点

  • 高危患者5年内进展为高级别上皮内瘤变或食管腺癌的风险是低危患者的15.2倍。
  • 高危组5年平均进展风险为21.5%,为Barrett食管人群5年患病率的4倍。
  • 低危组5年进展风险仅为1.85%。

核心结论

  • 该临床检测Esopredict可对Barrett食管患者未来肿瘤进展风险进行分层,识别可从内镜根除治疗或更频繁监测中获益的高危患者,以及可从减少监测中获益的低危患者。

研究设计与样本

  • 从6个中心获取240例Barrett食管患者的去标识内镜活检组织,确认其为未来进展者或非进展者,用一组甲基化特异性生物标志物检测分析组织。
  • 在独立验证集中按低危、低中危、高中危和高危4个分层级别评估检测性能。

主要发现

  • 相对于低危组患者,高危患者5年内进展为高级别上皮内瘤变或食管腺癌的可能性是高危患者的15.2倍。
  • 高危类别患者5年内进展为高级别上皮内瘤变或食管腺癌的平均风险为21.5%,为Barrett食管人群5年患病率的4倍。
  • 低危患者进展风险仅为1.85%。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Esophageal adenocarcinoma (EAC) is the second-most lethal cancer in the United States, with Barrett esophagus (BE) being the strongest risk factor. Assessing the future risk of neoplastic progression in patients with BE is difficult; however, high-grade dysplasia (HGD) and early EAC are treatable by endoscopic eradication therapy (EET), with survival rates of 90%. Thus, it would be beneficial to develop a molecular assay to identify high-risk patients, who merit more frequent endoscopic surveillance or EET, as well as low-risk patients, who can avoid EET and undergo less frequent surveillance. METHODS: Deidentified endoscopic biopsies were acquired from 240 patients with BE at 6 centers and confirmed as future progressors or nonprogressors. Tissues were analyzed by a set of methylation-specific biomarker assays. Test performance was assessed in an independent validation set using 4 stratification levels: low risks, low-moderate risks, high-moderate risks, and high risks. RESULTS: Relative to patients in the low-risk group, high-risk patients were 15.2 times more likely to progress within 5 years to HGD or EAC. For patients in the high-risk category, the average risk of progressing to HGD or EAC within 5 years was 21.5%, 4-fold the BE population prevalence within 5 years, whereas low-risk patients had a progression risk of only 1.85%. DISCUSSION: This clinical assay, Esopredict, stratifies future neoplastic progression risk to identify higher-risk patients with BE who can benefit from EET or more frequent surveillance and lower-risk patients who can benefit from reduced surveillance.

来源:Am J Gastroenterol,查看原文。版权归原作者所有。

引用

  1. Laun SE, Kann L, Braun J, et al. Validation of an Epigenetic Prognostic Assay to Accurately Risk-Stratify Patients With Barrett Esophagus. Am J Gastroenterol. 2024. PMID: 39140473. doi:10.14309/ajg.0000000000003030

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。